Bullous pemphigoid-Pipeline Insight, 2021 | Analytical Research Cognizance

Bullous pemphigoid-Pipeline Insight, 2021

Published by ARCDI001
Report ID 1667934
Published date Mar 30, 2021
Category Pharmaceuticals and Healthcare
Total Pages 60
Choose license type Buy Now
Request a Sample Enquiry Before Buying Check Discount

DelveInsight’s, “Bullous pemphigoid - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 9+ pipeline drugs in Bullous pemphigoid pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Global coverage
Bullous pemphigoid Understanding
Bullous pemphigoid: Overview
Bullous pemphigoid is an autoimmune subepidermal blistering disease. It is a rare skin condition that causes large, fluid-filled blisters. They develop on areas of skin that often flex such as the lower abdomen, upper thighs or armpits. Bullous pemphigoid often presents in people over 80 years of age, and mostly affects people over 50. It can occur in younger adults, but bullous pemphigoid in infants and children is rare. Bullous pemphigoid is the result of an attack on the basement membrane of the epidermis by IgG +/- IgE immunoglobulins (antibodies) and activated T lymphocytes (white blood cells). Bullous pemphigoid causes severe itch and (usually) large, tense fluid-filled blisters, which rupture forming crusted erosions. Histopathologic analysis, Direct immunofluorescence (DIF) studies, and /or Indirect immunofluorescence (IDIF) tests are done to diagnosis of bullous pemphigoid. Treatment for bullous pemphigoid is focused on healing the skin and relieving itching, while minimizing adverse side effects of medications.
"Bullous pemphigoid - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bullous pemphigoid pipeline landscape is provided which includes the disease overview and Bullous pemphigoid treatment guidelines. The assessment part of the report embraces, in depth Bullous pemphigoid commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bullous pemphigoid collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Bullous pemphigoid R&D. The therapies under development are focused on novel approaches to treat/improve Bullous pemphigoid.
Bullous pemphigoid Emerging Drugs Chapters
This segment of the Bullous pemphigoid report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bullous pemphigoid Emerging Drugs
Dupilumab: Regeneron/Sanofi
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling. Dupilumab (Dupixent) is approved in the U.S. to treat patients aged 6 years and older with moderate-to-severe atopic dermatitis. Dupixent is also approved in the EU and Japan to treat certain adults with severe CRSwNP. The drug is in Phase III clinical studies for bullous pemphigoid. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. Dupilumab was invented using Regeneron's proprietary VelocImmune technology. The FDA has granted orphan drug designation to Dupilumab or the treatment of bullous pemphigoid.
Avdoralimab: Innate Pharma
Avdoralimab (IPH5401) is a complement C5a receptor antagonist (Anti-C5aR-215) recombinant human monoclonal antibody. It specifically binds and blocks C5a receptors (C5aR1) expressed on subsets of myeloid-derived suppressor cells (MDSC) and neutrophils. Avdoralimab is being investigated in Phase II clinical trials for Bullous pemphigoid and COVID-19.
Further product details are provided in the report……..
Bullous pemphigoid: Therapeutic Assessment
This segment of the report provides insights about the different Bullous pemphigoid drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Bullous pemphigoid
There are approx. 10+ key companies which are developing the therapies for Bullous pemphigoid. The companies which have their Bullous pemphigoid drug candidates in the most advanced stage, i.e. Phase III include, Regeneron/Sanofi.
Phases
DelveInsight’s report covers around 9+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Bullous pemphigoid pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravitreal
Subretinal
Topical

Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bullous pemphigoid: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Bullous pemphigoid therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bullous pemphigoid drugs.

Bullous pemphigoid Report Insights
Bullous pemphigoid Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Bullous pemphigoid Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Bullous pemphigoid drugs?
How many Bullous pemphigoid drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bullous pemphigoid?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bullous pemphigoid therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Bullous pemphigoid and their status?
What are the key designations that have been granted to the emerging drugs?
Key Players
Regeneron
Sanofi
Innate Pharma
Amgen
Akari Therapeutics
Key Products
Dupilumab
Avdoralimab
Apremilast
Nomacopan

Introduction
Executive Summary
Bullous pemphigoid: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Bullous pemphigoid – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Bullous pemphigoid companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Bullous pemphigoid Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Dupilumab: Regeneron/Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Avdoralimab: Innate Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Nomacopan: Akari Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Bullous pemphigoid Key Companies
Bullous pemphigoid Key Products
Bullous pemphigoid- Unmet Needs
Bullous pemphigoid- Market Drivers and Barriers
Bullous pemphigoid- Future Perspectives and Conclusion
Bullous pemphigoid Analyst Views
Bullous pemphigoid Key Companies
Appendix

Table 1 Total Products for Bullous pemphigoid
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Bullous pemphigoid
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products